Literature DB >> 27226435

IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Benchang Guo1, Lu Zhang1, Nicholas Chiorazzi2, Thomas L Rothstein3.   

Abstract

Chronic lymphocytic leukemia (CLL) cells express poor levels of surface immunoglobulin (sIg), and many are minimally activated or anergic in response to B-cell receptor (BCR) crosslinking in vitro. Paradoxically, CLL cells in patients are highly activated through BCR signaling and expand in proliferation centers, suggesting that the function of sIg signaling is rescued. Here, we find that, compared with normal naïve B cells, CLL cells express a low level of total CD79b protein but normal levels of CD79a and IgM protein. Association of both CD79a and CD79b to IgM is markedly reduced. We further find that interleukin-4 (IL-4) markedly rescues CD79b and sIgM protein in CLL samples. These changes significantly enhance signaling in response to BCR crosslinking. Furthermore, we find that these changes are more pronounced in immunoglobulin heavy chain variable (IGHV)-unmutated CLL cells than IGHV-mutated CLL cells. The results described herein reveal that reduced sIgM is due to low expression of total CD79b protein in CLL cells. IL-4 substantially restores CD79b protein expression, sIgM expression, and BCR signaling.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27226435      PMCID: PMC4965907          DOI: 10.1182/blood-2015-11-682997

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

1.  Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.

Authors:  C Ian Mockridge; Kathleen N Potter; Isla Wheatley; Louise A Neville; Graham Packham; Freda K Stevenson
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

2.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells.

Authors:  Bradley T Messmer; Davorka Messmer; Steven L Allen; Jonathan E Kolitz; Prasad Kudalkar; Denise Cesar; Elizabeth J Murphy; Prasad Koduru; Manlio Ferrarini; Simona Zupo; Giovanna Cutrona; Rajendra N Damle; Tarun Wasil; Kanti R Rai; Marc K Hellerstein; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

3.  Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.

Authors:  Aleksandar Petlickovski; Luca Laurenti; Xiaoping Li; Sara Marietti; Patrizia Chiusolo; Simona Sica; Giuseppe Leone; Dimitar G Efremov
Journal:  Blood       Date:  2005-02-22       Impact factor: 22.113

4.  Cytokine expression in periapical granulation tissue as assessed by immunohistochemistry.

Authors:  K F Walker; D F Lappin; K Takahashi; J Hope; D G Macdonald; D F Kinane
Journal:  Eur J Oral Sci       Date:  2000-06       Impact factor: 2.612

5.  Antigen-stimulated dissociation of BCR mIg from Ig-alpha/Ig-beta: implications for receptor desensitization.

Authors:  B J Vilen; T Nakamura; J C Cambier
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

6.  Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta.

Authors:  R S Douglas; R J Capocasale; R J Lamb; P C Nowell; J S Moore
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

7.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.

Authors:  A C Fluckiger; J F Rossi; A Bussel; P Bryon; J Banchereau; T Defrance
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  15 in total

1.  Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Authors:  June H Myklebust; Joshua Brody; Holbrook E Kohrt; Arne Kolstad; Debra K Czerwinski; Sébastien Wälchli; Michael R Green; Gunhild Trøen; Knut Liestøl; Klaus Beiske; Roch Houot; Jan Delabie; Ash A Alizadeh; Jonathan M Irish; Ronald Levy
Journal:  Blood       Date:  2016-12-23       Impact factor: 22.113

Review 2.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 3.  The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.

Authors:  Elisa Ten Hacken; Maria Gounari; Paolo Ghia; Jan A Burger
Journal:  Leukemia       Date:  2018-12-16       Impact factor: 11.528

4.  Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.

Authors:  Pablo Elías Morande; Mariela Sivina; Angimar Uriepero; Noé Seija; Catalina Berca; Pablo Fresia; Ana Inés Landoni; Javier M Di Noia; Jan A Burger; Pablo Oppezzo
Journal:  Blood       Date:  2019-02-27       Impact factor: 25.476

Review 5.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

6.  IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.

Authors:  Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Rita Sabatini; Franca Falzetti; Mauro Di Ianni; Maria Paola Martelli; Federica Mezzasoma; Maria Pelullo; Pierfrancesco Marconi; Paolo Sportoletti; Isabella Screpanti; Emanuela Rosati
Journal:  Cell Death Dis       Date:  2018-11-26       Impact factor: 8.469

7.  Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia.

Authors:  Renee C Tschumper; Tait D Shanafelt; Neil E Kay; Diane F Jelinek
Journal:  Oncotarget       Date:  2019-01-01

Review 8.  Celebrating 20 Years of IGHV Mutation Analysis in CLL.

Authors:  Nicholas Chiorazzi; Freda K Stevenson
Journal:  Hemasphere       Date:  2020-01-22

Review 9.  Exploring the pathways to chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Francesco Forconi; Thomas J Kipps
Journal:  Blood       Date:  2021-09-09       Impact factor: 25.476

10.  In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia.

Authors:  Eve M Coulter; Andrea Pepper; Silvia Mele; Najeem'deen Folarin; William Townsend; Kirsty Cuthill; Elizabeth H Phillips; Piers E M Patten; Stephen Devereux
Journal:  Haematologica       Date:  2017-12-14       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.